Cencora, Inc.

▲ Bull Case

• ◆Specialty re-rating from logistics to healthcare services: If OneOncology + RCA demonstrate 4%+ consolidated gross margins by FY2028, market re-rates COR from distribution multiple (~15-16x) to healthcare services multiple (~19-22x), implying stock price of $418–$528 (56–97% upside).
• ◆GLP-1 upside optionality not priced in: Consensus models GLP-1 growth decelerating to 10-12% annually through FY2028. FDA approvals for cardiometabolic/CKD indications could accelerate prescriptions to 15-20% GLP-1 growth, driving 150–300 bps additional revenue growth and pulling forward FCF ramp.
• ◆Deleveraging catalyst 12–18 months away: Net debt of ~$17B (4x adjusted EBITDA) is primary multiple depressant. At $3.5–4.0B annual FCF and limited M&A appetite post-OneOncology, leverage falls to ≤2.5x EBITDA by FY2028, restoring buyback capacity and triggering 2–3 turn multiple expansion ($35–55/share).

▼ Bear Case

• ◆OneOncology impairment—PharmaLex 2.0: $7.4B acquisition structurally analogous to failed PharmaLex acquisition. If physician churn exceeds expectations and distribution synergy underperforms, Cencora could record $2–4B goodwill impairment by FY2028, sending GAAP EPS negative and stalling adjusted EPS growth.
• ◆WBA disruption materializes: WBA is largest customer; 1,200+ store closures already reducing volume. WBA Chapter 11 filing or material contract renegotiation would expose Cencora to $8–10B AR impairment, $25–40B annual revenue loss, and working capital unwind, potentially breaching debt covenants.
• ◆Revenue deceleration + leverage = sustained multiple compression: H1 FY2026 revenue growth of 4.7% may be new normal if GLP-1 growth normalizes to single digits. At 5% revenue growth, EPS compounds at 8-10% with no buyback capacity. At $17B debt, stock deserves 13-14x multiple, implying $231–$247 per share with no margin of safety.

“Central analytical disagreement: Is the specialty physician services acquisition strategy (RCA + OneOncology) a transformational investment in next earnings layer or expensive diversification destroying capital and complexity? Bulls (Barclays, UBS, Evercore at $300–$412 targets) emphasize RCA's early proof of model, specialty practices embedded with supply chain creating durable earnings, and COR's discount vs. MCK understating structural advantage. Bears (cautious post-Q2 FY2026) highlight OneOncology purchased at $7.4B fair value with minimal results history, PharmaLex failure proving overpayment pattern, and 4x+ leverage leaving no room for execution errors. Debate resolves on FY2027 Q1 results (February 2027): if OneOncology drives GP margin above 2.85% and EPS runs $1.50–2.00 above consensus, bull case wins decisively.”

• ◆Q3 FY2026 (August 2026): First full OneOncology quarterly result; US HC GP margin must exceed 2.85% for bull case confirmation
• ◆Q4 FY2026 (November 2026): Full-year FY2026 GP margin confirmation; threshold ≥3.70% signals thesis on track
• ◆Q1 FY2027 (February 2027): OneOncology first full fiscal year quarter and definitive bull/bear signal for market
• ◆FDA approvals for new GLP-1 indications (MASH, CKD, sleep apnea) through 2026–2027 extending volume runway
• ◆Net debt normalization below $14.0B by FY2027 triggering multiple re-rate and buyback resumption
• ◆WBA volume trajectory stability—key risk indicator for customer concentration exposure

• ◆WBA financial disruption (P=15–20%): Largest customer; pharmacy closures reducing volume; bankruptcy or material contract renegotiation could trigger $8–10B AR impairment and $25–40B revenue loss
• ◆OneOncology impairment (P=15–20%): $7.4B acquisition with physician integration risk; PharmaLex failure ($1.14B impairment on $1.4B acquisition) is base-rate comparator
• ◆GLP-1 growth deceleration faster than modeled (P=25%): Price negotiation (IRA) or biosimilar entry could accelerate GLP-1 price deflation, reducing revenue growth to 2–3%
• ◆Leverage overhang persists (P=30%): If acquisition disappoints and FCF below $3B, net debt stays elevated, buyback capacity eliminated, multiple stays compressed at 13–14x
• ◆Regulatory action (P=5–10%): 340B program changes, DEA controlled substance actions, or FTC action targeting Big Three oligopoly
• ◆Cybersecurity breach (P=10%): Drug distribution is critical infrastructure; supply chain disruption from breach poses operational and reputational risk